A breakthrough ultrasound technology that unlocks earlier detection of pancreatic cancer through enhanced cytopathology.

Adenocyte has developed and patented LINFU®, a non-invasive ultrasound-based technology that significantly increases the natural exfoliation of epithelial cells into a surrounding body fluid, dramatically enhancing the cytopathology specimens used to screen for dysplasia and cancer. The first clinical application enriches the pancreatic juice cytopathology specimen used to screen high-risk asymptomatic patients for ductal dysplasia (PanIN-2 and PanIN-3) and early carcinoma (PDAC), addressing a disease with a ~4% 5-year survival rate at advanced stage that is projected to become the second leading cause of cancer death in the US by 2030. LINFU® is in early commercial phase in the US.